• Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress.
• These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts.
• We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these conferences, could shape Tarsus Pharmaceuticals’ broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Tarsus Pharmaceuticals Investment Narrative Recap

Tarsus is largely a one-product story built around XDEMVY, so you need to believe its real-world adoption can continue to expand while spending remains productive. The recent conference appearances primarily reinforce awareness and visibility rather than changing the near term picture, where the key catalyst is sustained prescription growth and the main risk is that uptake or retreatment rates slow against a backdrop of elevated commercial costs.

Against this backdrop, the recent first dosing in the Calliope Phase 2 study for TP-05 in Lyme disease prevention is especially relevant, as it highlights Tarsus’ effort to diversify beyond XDEMVY. While TP-05 is still early and not a near term revenue driver, progress here matters because a successful pipeline could gradually reduce the company’s heavy dependence on a single product and potentially balance the risks tied to XDEMVY adoption and reimbursement.

Yet beneath the optimism around XDEMVY’s momentum, investors should be aware of the growing tension between heavy commercial spend and the possibility that...

Tarsus Pharmaceuticals' narrative projects $1.1 billion revenue and $632.5 million earnings by 2029. This requires 28.3% yearly revenue growth and a $680.8 million earnings increase from -$48.3 million.

Uncover how Tarsus Pharmaceuticals' forecasts yield a $94.11 fair value, a 54% upside to its current price.

Exploring Other Perspectives

While recent conferences spotlight XDEMVY’s traction, the most cautious analysts were assuming about US$988 million of revenue and roughly US$188 million of earnings by 2029, so you should weigh how these more pessimistic assumptions about pricing pressure and payer leverage might evolve as new information like the latest XDEMVY adoption data comes through and compare them with your own expectations.

Explore 4 other fair value estimates on Tarsus Pharmaceuticals - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tarsus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tarsus Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.